Comparison of the effects of rebamipide with those of cimetidine on chronic gastritis associated with Helicobacter pylori in Mongolian gerbils

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 18, Issue 1, 2003, Pages 1-7

  Hicuchi, K ^a   Tanigawa, T ^a   Hamaguchi, M ^a   Takashima, T ^a   Sasaki, E ^a   Shiba, M ^a   Tominaga, K ^a   Fujiwara, Y ^a   Oshitani, N ^a   Matsumoto, T ^a   Watanabe, T ^a   Arakawa, T ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CIMETIDINE; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; GASTRIN; MYELOPEROXIDASE; REBAMIPIDE; TUMOR NECROSIS FACTOR ALPHA; ALANINE; ANTIULCER AGENT; DRUG DERIVATIVE; PEROXIDASE; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BACTERIAL COLONIZATION; CHRONIC GASTRITIS; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GASTRIN BLOOD LEVEL; GERBIL; HELICOBACTER PYLORI; HISTOPATHOLOGY; IMMUNOMODULATION; INOCULATION; LONG TERM CARE; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; STOMACH WEIGHT; ANIMAL; ARTICLE; BLOOD; COMPARATIVE STUDY; ENZYMOLOGY; GASTRITIS; HELICOBACTER INFECTION; METABOLISM; MICROBIOLOGY; NEUTROPHIL;

ALANINE; ANIMALS; ANTI-ULCER AGENTS; CHEMOKINES; CIMETIDINE; GASTRINS; GASTRITIS; GERBILLINAE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MALE; NEUTROPHILS; PEROXIDASE; QUINOLONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042284553     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01598.x     Document Type: Conference Paper

References (49)

1. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol 1987; 142: 23-9.
2. Kishimoto S, Fujimura J, Machino H, et al. Therapeutic effects of oral rebamipide and in combination with cimetidine on experimental gastritis in rats. Res Commun Chem Pathol Pharmacol 1992; 78: 259-77.
3. Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K. Rebamipide, a novel prostaglandin-inducer, accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Dig Dis Sci 1995; 40: 2469-72.
4. Watanabe T, Higuchi K, Hamaguchi M, et al. Rebamipide prevents delay of acetic acid-induced gastric ulcer healing caused by Helicobacter pylori unfection in Mongolian gerbils. Dig Dis Sci 2002; 47: 1582-9.
5. Higuchi K, Arakawa T, Nebiki H, et al. Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci 1998; 43(9 Suppl.): 99-106(S).
6. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 1993; 38: 1441-9.
7. Yoshida N, Yoshikawa T, Iinuma S, et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996; 41: 1139-44.
8. Murakami K, Okajima K, Uchiba M, et al. Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig Dis Sci 1997; 42: 319-25.
9. Suzuki M, Miura S, Mori M, et al. Rebamipide, a novel anti-ulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 1994; 35: 1375-8.
10. Naito Y, Yoshikawa T, Tanigawa T, et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 1995; 18: 117-23.
11. Sakurai K, Yamasaki K. Protective effect of rebamipide against hydrogen peroxide-induced hemorrhagic mucosal lesions in rat stomach. Jpn J Pharmacol 1994; 64: 229-34.
12. Haruma K, Ito M, Kido S, et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci 2002; 47: 862-7.
13. Talley NJ, Riff DS, Schwartz H. et al. Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 1603-11.
14. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102: 720-7.
15. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.
16. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19(Suppl. 1): 37-43(S).
17. Scotiniotis IA, Rokkas T, Furth EE, Rigas B, Shiff SJ. Altered gastric epithelial cell kinetics in Helicobacter pylori-associated intestinal metaplasia: implications for gastric carcinogenesis. Int J Cancer 2000; 85: 192-200.
18. Hamaguchi M, Watanabe T, Higuchi K, et al. Mechanisms and roles of neutrophil infiltration in stress-induced gastric injury in rats. Dig Dis Sci 2001; 46: 2708-15.
19. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206-9.
20. Dixon ME, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis. Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
21. Sharma SA, Tummuru MK, Blaser MJ, Kerr LD. Activation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-kappa B in gastric epithelial cells. J Immunol 1998; 160: 2401-7.
22. Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 1997; 41: 442-51.
23. Yamaoka Y, Kita M, Kodama T, Sawai N, Imanishi J. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996; 110: 1744-52.
24. Fan XG, Chua A, Fan XJ, Keeling PW. Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection. J Clin Pathol 1995; 48: 133-6.
25. Moss SF, Legon S, Davies J, Calam J. Cytokine gene expression in Helicobacter pylori associated antral gastritis. Gut 1994; 35: 1567-70.
26. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 1998; 43(9 Suppl.): 160-166(S).
27. Choi KW, Lee YC, Chung IS, et al. Effect of rebamipide in treatment of Helicobacter pylori-associated duodenal ulcer: attenuation of chemokine expression and nitrosative damage. Dig Dis Sci 2002; 47: 283-91.
28. Hong KW, Kim KE, Rhim BY, Lee WS, Kim CD. Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. Dig Dis Sci 1998; 43(9 Suppl.): 154-159(S).
29. Kim H, Seo JY, Kim KH. Inhibition of lipid peroxidation, NF-kappaB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci 2000; 45: 621-8.
30. Takahashi K, Tanaka S, Ichikawa A. Effect of cimetidine on intratumoral cytokine expression in an experimental tumor. Biochem Biophys Res Commun 2001; 281: 1113-9.
31. Kikuchi T, Kato K, Ohara S. et al. The relationship between persistent secretion of RANTES and residual infiltration of eosinophils and memory T lymphocytes after Helicobacter pylori eradication. J Pathol 2000; 192: 243-50.
32. Warren JR. Gastric pathology associated with Helicobacter pylori. Gastroenterol Clin North Am 2000; 29: 705-51.
33. Tepes B, Kavcic B, Zaletel LK, et al. Two- to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol 1999; 188: 24-9.
34. Ando T, Kusugami K, Ohsuga M, et al. Differential normalization of mucosal interleukin-8 and interleukin-6 activity after Helicobacter pylori eradication. Infect Immun 1998; 66: 4742-7.
35. Yokota S, Geppert TD, Lipsky PE. Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-α. J Immunol 1988; 140: 531-6.
36. Jelinek DF, Lipsky PE. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-α and interleukin 1. J Immunol 1987; 139: 2970-6.
37. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Laboratory Invest 1987; 56: 234-48.
38. Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA Jr. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 1986; 136: 1680-7.
39. Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-α increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol 1986; 136: 4548-53.
40. Strieter RM, Chensue SW, Basha MA, et al. Human alveolar macrophage gene expression of interleukin-8 by tumor necrosis factor-α lipopolysaccharide, and interleukin-1 beta. Am J Respir Cell Mol Biol 1990; 2: 321-6.
41. Moss SF, Calam J, Agarwal B, Wang S, Holt PR. Induction of gastric epithelial apoptosis by Helicobacter pylori. Gut 1996; 38: 498-501.
42. Leung WK, Yu J, To KF, et al. Apoptosis and proliferation in Helicobacter pylori-associated gastric intestinal metaplasia. Aliment Pharmacol Ther 2001; 15: 1467-72.
43. Houghton J, Macera-Bloch LS, Harrison L, Kim KH, Korah RM. Tumor necrosis factor alpha and interleukin 1beta up-regulate gastric mucosal Fas antigen expression in Helicobacter pylori infection. Infect Immun 2000; 68: 1189-95.
44. Xia HH, Talley NJ. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol 2001; 96: 16-26.
45. Levi S, Beardshall K, Haddad G. et al. Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet 1989; 1: 1167-8.
46. Mulholland G, Ardill JE, Fillmore D, et al. Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17. Gut 1993; 34: 757-61.
47. Konturek SJ, Konturek PC, Hartwich A, et al. Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies. Regul Pept 2000; 93: 13-9.
48. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
49. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000; 118: 36-47.